This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Codexis Awarded Biofuels Enzyme Patent

Codexis, Inc. (Nasdaq:CDXS), a developer of industrial enzymes to enable the production of biofuels, biobased chemicals, and pharmaceutical intermediates, today announced it has been awarded a key patent from the U.S. Patent and Trademark Office covering an important component of the company’s proprietary enzymatic technology that can be used for production of cellulosic biofuels.

Codexis specifically received U.S. Patent No. 8,143,050, “Recombinant Beta-Glucosidase Variants for Production of Soluble Sugars from Cellulosic Biomass”.

“This patent covers an enzyme group essential in the conversion of cellulosic biomass to fermentable sugars, which can subsequently be used for the production of a wide range of cellulosic biofuels,” said Peter Strumph, Interim Chief Executive Officer. “This adds to the strong Codexis intellectual property portfolio already in place and further strengthens the competitive position in the biofuels market for both Codexis and Shell, our advanced biofuels development partner.”

This is the latest patent to be added to the company’s portfolio of intellectual property which also includes patents covering the company’s CodeXyme™ Cellulase Enzymes and CodeEvolver™ directed evolution technology platform, among others.

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the Codexis intellectual property portfolio and the patent on biofuels technology referred to in this press release. Important factors that could cause actual results to differ materially from the forward-looking statements in this press release include risks that we may not be able to enforce our intellectual property rights and that we may not be able to compete if we lose some of our intellectual property rights. Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,882.12 -103.49 -0.61%
S&P 500 1,963.18 -9.65 -0.49%
NASDAQ 4,392.6720 -26.3620 -0.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs